

# Interference between Venus-A Valve and Anterior Mitral Valve Leaflets after Transcatheter Aortic Valve Replacement: Insight from FEops HEARTguide simulation

1

2

3 Yong Wang<sup>1†</sup>, Ting Liu<sup>1†</sup>, Ying Zeng<sup>1</sup>, Nic Debusschere<sup>2</sup>, Giorgia Rocatello<sup>2</sup>, Sihang Cheng<sup>3</sup>,  
4 Ping Li<sup>1</sup>, Dehui Qian<sup>1</sup>, Shiyong Yu<sup>1</sup>, Jun Jin<sup>1\*</sup>

5

6 1 Department of Cardiology, Institute of Cardiovascular Research, The Second Affiliated Hospital  
7 of Army Medical University, Chongqing, China.

8 2 FEops NV, Ghent, Belgium.

9 3 Venus Medtech, Hangzhou, China.

10

11 **Running title:** Prosthesis-AML interference following TAVR

12

13 † These authors contributed equally to this work.

14 \* The corresponding author. Jun Jin, Department of Cardiology, Institute of Cardiovascular  
15 Research, The Second Affiliated Hospital of Army Medical University, Chongqing, China. E-mail:  
16 xqyyjinjun@163.com

17 This manuscript contains 3061 words, 3 Tables and 3 Figures.

18 **Keywords:** transcatheter aortic valve replacement, anterior mitral leaflet, interference,  
19 computer simulation.

20

21

22

23

## 24 Abstract

25 **Background** Scarce data exist regarding the occurrence of mitral valve interference after  
26 transcatheter aortic valve replacement (TAVR) with Venus-A valve implantation. Several case  
27 reports have noted that the anterior mitral leaflet (AML) is mechanically affected by the  
28 prosthesis frame, particularly when implanted in a low position. This study aimed to investigate  
29 the potential factors influencing the clinical outcomes of AML interference after Venus-A valve  
30 implantation.

31 **Methods** We retrospectively included 20 severe aortic valve stenosis patients who had undergone  
32 TAVR and had been implanted with the Venus-A valve at our hospital between October 2020 and  
33 June 2021. Pre- and post-procedural CT scans were used for the FEops HEARTguide simulation.  
34 Anatomically influencing factors were measured using the 3mensio software and derived from the  
35 FEops HEARTguide. The prosthesis-AML interference (PAI) was defined when it met both of  
36 two criteria: 1) significant interference and limited AML movement shown by transthoracic or  
37 transoesophageal echocardiography, and 2) more than half cell intersection between the simulated  
38 Venus-A valve and the reconstructed AML revealed by the FEops HEARTguide. Anatomical  
39 factors and clinical outcomes were compared between the PAI and non-PAI groups.

40 **Results** Nine PAI patients and 11 non-PAI cases were identified. PAI was associated with shorter  
41 mitral-aortic annulus distance ( $2.7 \pm 1.7$  mm vs  $5.0 \pm 2.2$  mm,  $P = 0.019$ ), larger prosthesis valve  
42 size ( $P = 0.013$ ), deeper implantation ( $12.2 \pm 3.3$  mm vs  $6.2 \pm 2.9$  mm at non-coronary cusp side,  $P$   
43  $< 0.001$ ) and less calcification of non-coronary cusp (median calcification score,  $52.2$  mm<sup>3</sup> vs  
44  $156.0$  mm<sup>3</sup>,  $P = 0.046$ ). Regarding the clinical impact, PAI was associated with a higher rate of  
45 moderate or severe perivalvular leakage before discharge than those associated with the absence  
46 of PAI, with no difference in haemodynamic parameters and incidence of adverse events at the  
47 30-day and 12-month follow-ups between the groups.

48 **Conclusions** Interference between the Venus-A prosthesis valve and AML after TAVR was  
49 associated with a shorter mitral-aortic annulus distance, larger prosthesis usage, greater  
50 implantation depth, and less calcification of the non-coronary cusp. However, further studies are  
51 required to explore its long-term clinical impact.

## 52 1 Introduction

53 Transcatheter aortic valve replacement (TAVR) is the leading therapeutic strategy for aortic  
54 valve replacement in patients with severe symptomatic AS (1). As the anterior mitral annulus is  
55 anatomically linked to both the left and non-coronary aortic cusps through a shared fibrous rim  
56 (2), the prosthesis frame mechanically interferes with the anterior mitral leaflet (AML), especially  
57 when implanted in a low position. Several case reports have reported that deep aortic prosthetic  
58 valve implantation may impair adequate AML opening (3,4), even led to direct erosive  
59 perforation and infective endocarditis (5-7). However, the existing knowledge about this rarely  
60 described complication remains limited.

61 A self-expandable valve purportedly has a higher risk of AML interference than that  
62 associated with a balloon-expandable valve owing to its long prosthesis frame [4]. The  
63 self-expandable Venus-A valve was the first approved transcatheter heart prosthesis and is the  
64 most widely used valve in Mainland China. The design characteristics of the Venus-A valves have

65 been previously reported in detail (8). Data on mitral valve interference after Venus-A valve  
66 implantation are scarce. Patient-specific computational modelling of TAVR with the FEops  
67 HEARTguide (FEops nv, Ghent, Belgium) based on pre-procedural dual-source computed  
68 tomography (DSCT) could accurately predict device-anatomy interactions between a  
69 self-expandable transcatheter device model and the surrounding anatomical structures (9-11), in  
70 both tricuspid and bicuspid aortic valve anatomy (11-14). Three-dimensional computer models  
71 can provide detailed insights to help investigate the interference between the AML and the  
72 prosthesis frame.

73 In this exploratory study, we sought to explore prosthesis-AML interference in patients with  
74 aortic valve stenosis treated with the Venus-A valve through patient-specific computer simulation.

## 75 **2 Materials and Methods**

### 76 **2.1 Patient population**

77 This single-centre, retrospective, observational study included 20 patients with severe aortic  
78 stenosis who successfully underwent TAVR at our hospital. All patients who had undergone  
79 transfemoral TAVR using a first-generation self-expandable Venus-A valve (Venus MedTech Inc.,  
80 Hangzhou, China), and those who had undergone a second valve implantation (valve-in-valve)  
81 were excluded. The design characteristics of the Venus-A valves have been previously reported in  
82 detail (8). Preprocedural and postprocedural computed tomography scans were performed in 20  
83 and 17 patients, respectively, using DSCT (SOMATOM Definition Flash, Siemens Medical  
84 Solutions, Germany). The heart team discussed the indications for TAVR, and the size of the  
85 prostheses was determined based on the aortic root DSCT.

86 This study was approved by the Research Ethics Committee of the Second Affiliated  
87 Hospital (Xinqiao Hospital) of the Army Military Medical University, and the requirement for  
88 informed consent was waived because of its retrospective design.

### 89 **2.2 Data collection**

90 Baseline clinical information, echocardiographic, DSCT, procedural, and clinical follow-up  
91 data were collected. All patients underwent echocardiography and electrocardiography before  
92 discharge and at both 30-day and 12-month follow-ups. Postprocedural DSCT was performed 6–  
93 12 months after TAVR (mean 8.2 months). DSCT data were retrospectively analysed using the  
94 3mensio software (Pie Medical, Bilthoven, Netherlands). The aortic root structure was measured  
95 in the 40% systolic phase. The aortic annulus was defined as the virtual basal plane containing the  
96 basal attachment of the three aortic cusps. Sizes of the annulus, left ventricular outflow tract,  
97 sinotubular junction, and ascending aorta were measured. Aortic valve morphology was recorded  
98 using the Sievers classification (15). The aortic valve calcification volume was automatically  
99 measured using a calcification threshold of 850 HU. Clinical events were recorded according to  
100 Valve Academic Research Consortium-3 (VARC-3) criteria (16). Two experienced sonographers  
101 independently checked the position of the TAVR prosthesis and its relationship with the AML,  
102 and evaluated the morphology and motion of the AML. The degree of their interaction was graded  
103 as follows: 0, no interference between prosthesis and AML; 1, interference but the motion of AML  
104 was not obviously affected; and 2, significant interference and limited AML movement. The  
105 kappa coefficient of agreement was 0.92. Prosthesis AML interference (PAI) was defined if met

106 both of the 2 criteria:1) significant interference and limited AML movement shown by  
107 transthoracic or transoesophageal echocardiography, and 2) more than half-cell intersection  
108 between the simulated Venus-A valve and the reconstructed AML revealed by computer  
109 simulation.

### 110 **2.3 Computer simulation**

111 Briefly, preprocedural and postprocedural CT scans were obtained from 20 and 17 patients,  
112 respectively. Preprocedural cardiac CT images were used to reconstruct finite element models of  
113 the aortic root, including native calcified aortic leaflets, left ventricle, left atrium, and mitral  
114 leaflets (**Figure 1a-1b-1c**). Different material properties were used to model the native aortic wall  
115 ( $E=0.6$  MPa,  $\nu=0.3$ ), native leaflet tissue ( $E=2$  MPa,  $\nu=0.45$ ) and calcium nodules ( $E=4$  MPa,  
116  $\nu=0.3$ , Yield stress = 0.6 MPa) (9,10). The left ventricle, left atrium, and mitral leaflets were used  
117 for visualisation purposes only to evaluate the interference between the AML and simulated  
118 device. Therefore, no material properties are assigned to these structures.

119 In the finite element analysis simulation, the crimped Venus-A valve model was positioned  
120 coaxially within the aortic root and deployed by retracting the sheath. In each simulation, the  
121 device size and position were consistent with those used in the clinical procedure. Device  
122 implantation was iteratively simulated until the final device position matched the actual depth of  
123 implantation, as measured from post-procedural CT images in 17 patients (**Figure 1d-1f**). In 3  
124 patients, the final implantation depth at the noncoronary and left coronary cusps was derived from  
125 DSA.

### 126 **2.4 Morphological Interference Analysis**

127 The inner linings of the left ventricle and left atrium were segmented from the CT images.  
128 The mitral and aortic annuli were manually indicated on CT images. The mitral valve leaflets  
129 were reconstructed by mapping a template mesh with the leaflets visible on CT images. The left  
130 ventricle, left atrium, and mitral leaflets were used for visualisation purposes only, whereas the  
131 aortic annual plane and mitral annulus were used to calculate the mitral-aortic annulus length  
132 ( distance) and angle.

133 A reference plane was assigned to each mitral valve (**Figure 2**), with its origin at the centre  
134 of the mitral annulus and its normal vector aligned with the line connecting the posteromedial and  
135 anterolateral trigones. This plane intersects the mitral and aortic annuli. The mitral-aortic annulus  
136 length was defined as the minimum distance between the intersection points. The mitral and aortic  
137 annulus normal vectors were defined by determining the best-fitting planes using both closed  
138 curves. The mitral-aortic annulus angle was defined as the angle between the respective normal  
139 vectors. Morphological interference was defined as more than half of the cells of the Venus A  
140 valve intersecting the reconstructed AML in the simulation results. **Figure 3** shows two cases with  
141 no morphological interference (**Figure 3a-3b**) and one with morphological interference (**Figure**  
142 **3c**). **Supplementary Figure 1** defined “half-cell intersection”.

### 143 **2.5 Statistical Analysis**

144 Continuous variables with normal distribution are expressed as mean  $\pm$  standard deviation;  
145 those with skewed distribution are expressed as median (lower and upper quartile), while

146 categorical variables are reported as numbers (proportion). The independent sample *t*-test or  
147 Mann-Whitney *U* test was used to compare the means between the two groups, and Fisher's exact  
148 test was used for categorical variables. All statistical tests were 2-tailed, with  $P < 0.05$ . considered  
149 statistically significant. Statistical analyses were performed using SPSS (version 26.0; Chicago,  
150 Armonk, NY, USA).

### 151 3 Results

152 As presented by the FEops HEARTguide, six cases were identified without an intersection  
153 between the prosthesis frame and AML (**Figure 3a**), five had an intersection  $<$  half cell (**Figure**  
154 **3b**), and nine cases were identified with more than half of the cells (**Figure 3c**). Consistently,  
155 echocardiography showed that all 9 patients with an intersection of more than half of the cells  
156 showed significant interference and limited AML movement, whereas those with an intersection  
157  $<$ half-cell showed no limited AML movement. Therefore, 9 PAI cases and 11 non-PAI cases were  
158 identified.

159 As shown in **Table 1**, the groups did not differ in terms of sex, age, and other clinical  
160 characteristics, while the presence of atrial fibrillation ( $P = 0.050$ ) and more than mild mitral  
161 regurgitation was higher ( $P = 0.028$ ) in the PAI group. The left ventricular anteroposterior  
162 diameter was larger ( $P = 0.028$ ), while the ejection fraction and fractional shortening were lower  
163 in the PAI group (both  $P < 0.05$ ).

164 The anatomical characteristics of the patients are shown in **Table 2**. According to the  
165 computer simulation parameters, the length between aortic-mitral annulus was shorter in PAI  
166 cases ( $2.7 \pm 1.7$  mm vs  $5.0 \pm 2.2$  mm,  $P = 0.019$ ), but the angle showed no difference (**Figure 2**).  
167 According to the CT parameters, PAI was associated with a larger annulus and LVOT (all  $P$   
168  $< 0.05$ ). Nevertheless, less calcification of the non-coronary cusp was observed in the PAI group  
169 ( $P = 0.046$ ). The procedural characteristics and in-hospital clinical outcomes are listed in **Table 3**.  
170 The proportion of larger size prosthesis application was higher ( $P = 0.013$ ), and the implantation  
171 depth was significantly deeper in patients with PAI ( $12.2 \pm 3.3$  mm vs  $6.2 \pm 2.9$  mm at NCC side,  $P$   
172  $< 0.001$ , and  $14.3 \pm 4.7$  mm vs  $7.7 \pm 3.1$  mm at LCC side,  $P = 0.002$ , respectively). Moreover, the  
173 incidence of moderate perivalvular leakage (PVL) was higher in the PAI group (5/9 vs 0/11,  $P =$   
174  $0.008$ ). The incidence of new-onset left bundle branch block was higher in the PAI group;  
175 however, the difference was not statistically significant ( $P = 0.070$ ).

176 Regarding clinical outcomes, no significant differences were observed in aortic flow velocity,  
177 aortic pressure gradient, or clinical events such as mortality, stroke, PVL, and heart failure  
178 between the two groups at both the 30-day and 12-month follow-ups. In particular, we observed  
179 special adverse consequences of PAI according to previous reports (3-6), and no new-onset mitral  
180 stenosis, infective endocarditis, or mitral valve perforation occurred in either group (**Table 3**).

### 181 4 Discussion

182 To our knowledge, this is the first report to explore the anatomical influencing factors and  
183 midterm clinical outcomes of PAI following self-expandable TAVR. The Venus-A valve was  
184 chosen, and the FEops HEARTguide simulation was used to visually exhibit interference.  
185 Additionally, the clinical and haemodynamic outcome parameters were compared between the  
186 PAI and non-PAI groups. The results showed that PAI was associated with a shorter mitral-aortic

187 annulus distance, larger prosthesis valve size, deeper implantation, and less calcification of the  
188 non-coronary cusp. Moreover, it was associated with a higher rate of moderate or severe  
189 perivalvular leakage before discharge, but haemodynamic parameters and the incidence of  
190 adverse events at the 30-day and 12-month follow-ups were not affected.

191 Being in close contact with the left fibrous trigone (2,17), the AML is prone to interference  
192 with the prosthetic valve. In fact, our previous study found that in patients with pure native aortic  
193 valve regurgitation, 14 of 61 (23.0%) patients who received Venus-A prosthesis implantation had  
194 significant PAI following TAVR (18). To some extent, PAI should be considered a common  
195 complication (7,19,20), but it has rarely been described and is not covered by the VARC-3 criteria  
196 (16). In other words, the lack of consistent definitions and measurement standards in daily clinical  
197 practice has hindered the reporting of PAI. This report attempts to draw attention to this neglected  
198 clinical complication, which has been excluded from the standardised outcome reports of patients  
199 with TAVR. Given that there is currently no standardised definition, in this study, we first propose  
200 a diagnostic criterion for PAI that includes both functional and morphological assessments. To  
201 precisely describe their interaction visually, we used the FEops HEARTguide based on DSCT for  
202 computer simulation. The FEops HEARTguide has been previously reported to accurately predict  
203 the device-anatomy interaction between a self-expandable transcatheter device model and the  
204 surrounding anatomical structures (9-11), even in Chinese patients implanted with Venus-A valves  
205 (11,21,22). However, previous studies have mainly described the prosthesis frame morphology  
206 and complications such as conduction disturbance and PVL after valve implantation. In the  
207 present study, we first revealed the interaction between the prosthesis frame and the AML using  
208 the FEops HEARTguide. However, because of the limited accuracy of the FEops HEARTguide in  
209 patients who underwent valve-in-valve TAVR, this study excluded those subjects, while most  
210 valve-in-valve cases were supposed to have PAI in view of their deep implantation. In the future,  
211 improvement of the FEops HEARTguide or other technologies, such as 3D printing, may help in  
212 the evaluation of these patients.

213 As mentioned previously, deep implantation of a long-frame prosthesis is a significant risk  
214 factor for PAI. However, in a recently published case report, AML perforation occurred  
215 immediately after balloon predilatation due to folded leaflet calcifications distributed at the level  
216 of the non-coronary sinus toward the medial aspect of the mitral-aortic curtain (23). The authors  
217 considered that the distribution of bulky calcifications could also play a role in AML injury during  
218 TAVR procedure (23). In the present study, we further recognised several other potential risk  
219 factors, such as shorter mitral-aortic annulus distance, use of a larger prosthesis valve, and less  
220 calcification of the non-coronary cusp. The distance of the mitral aortic annulus varies across  
221 patients, and in those with prosthetic mitral valves (PMVs) undergoing TAVR, PMV-to-aortic  
222 annulus distances of <7 mm are independent risk factors for valve embolization (24). However,  
223 we could not provide a threshold value of the mitral-aortic annulus distance for risk stratification  
224 given the small sample size in this descriptive and exploratory study. Theoretically, the angle  
225 between the aortic/mitral planes should also influence their interference, but we failed to detect a  
226 difference in the mitral-aortic annulus angle between the PAI and non-PAI groups (131.4° vs  
227 126.2°,  $P=0.333$ ), which may be partially explained by the limited sample size. A large prosthesis  
228 was also supposed to shorten the distance between the AML and the implanted valve frame owing  
229 to its wide bottom in the LVOT. Moreover, we noticed that the difference of calcification volume  
230 at NCC was statistically significant between the groups, the reason remains speculative, but a  
231 possible explanation is that the distribution of eccentric calcification in the aortic valve facilitate

232 deeper implantation (25).

233 Deep implantation may explain post-procedural PVL and new-onset left bundle branch block,  
234 but the adverse impact of PAI on 30-day and 12-month clinical prognoses was not detected in the  
235 present study, partially because of the small sample size and relatively short follow-up duration.  
236 However, we noticed that the PAI group showed a higher rate of heart failure at the 30-day and  
237 12-month follow-ups (4/9 vs 1/11), which may be caused by a higher rate of PVL in the PAI  
238 group; the higher rate of concomitant atrial fibrillation at baseline (5/9 vs 1/11) may also worsen  
239 cardiac function. A previous study reported five cases of post-TAVR mitral valve stenosis due to  
240 PAI, with a mean trans-mitral gradient ranging from 7 mmHg to 13 mmHg, three of which were  
241 treated with a conservative approach, and two others received urgent surgery (4). In the present  
242 study, the trans-mitral gradient remained at <5 mmHg in all PAI cases. This may be explained by  
243 the exclusion of valve-in-valve cases, in which patients were supposed to have a more severe  
244 impact on AML motion.

245 Nevertheless, the present report calls attention to this common complication regarding the  
246 devastating consequences of potential AML perforation, delayed mitral stenosis, and infective  
247 endocarditis (4-7). Furthermore, this study also emphasises the need for meticulous patient  
248 selection and strategy decision in those with a large annulus, short mitral-aortic annulus distance,  
249 and less calcification of the non-coronary cusp. To reduce the risk of PAI, a resheathable or  
250 short-frame device may be considered. Patients who may benefit from concomitant percutaneous  
251 mitral valve repair should also be carefully evaluated before developing final treatment strategies.

#### 252 4.1 Limitations

253 The present study had several limitations. First, given the relatively small sample size and  
254 retrospective observational design, formal statistical analysis was not performed. Therefore,  
255 caution should be exercised when drawing firm conclusions owing to unmeasured confounders.  
256 Second, only the first-generation Venus-A valve was used in this study, and its applicability to  
257 other devices requires confirmation. However, the Venus-A valve is morphologically similar to  
258 the Medtronic CoreValve, and our findings may provide information to those who undergo  
259 CoreValve device implantation. Second, the HEARTguide is not generally used in clinical  
260 practice; simpler detection methods for PAI are needed. Third, other factors, such as extensive  
261 calcification of the aorto-mitral continuity or mitral ring, may also increase the risk of PAI and  
262 new-onset mitral valve stenosis, while no patients had severe calcification of the aorto-mitral  
263 continuity or mitral ring, and this factor was not included in the analysis. Other limitations  
264 included patient selection bias, short follow-up duration, and lack of an independent core  
265 laboratory or adjudication of clinical events.

#### 266 5 Conclusions

267 PAI is associated with a shorter mitral-aortic annulus distance, larger prosthesis usage,  
268 deeper implantation, and less calcification of the non-coronary cusp. However, further studies are  
269 required to explore its long-term clinical impact.

#### 270 6 Captions

271 **Table 1.** Baseline characteristics of PAI group and Non-PAI group

272 Data are presented as mean  $\pm$  standard deviation or median (lower quartile, upper quartile). PAI,  
273 Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society  
274 of Thoracic Surgeons. NCC, Non coronary cusp; RCC, Right coronary cusp; LCC, Left coronary  
275 cusp.

276 **Table 2.** Intra-Procedural data and in-hospital outcomes of the two groups

277 Data are presented as mean  $\pm$  standard deviation or median (lower quartile, upper quartile). PAI,  
278 Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society  
279 of Thoracic Surgeons. NCC, Non coronary cusp; LCC, Left coronary cusp. LBBB, left bundle  
280 branch block. NA, Not Applicable.

281 **Table 3.** The 30-day and 12-month clinical outcomes of the two groups

282 Data are presented as mean  $\pm$  standard deviation. PAI, Prosthesis-anterior mitral leaflet  
283 interference; NYHA, New York Heart Association; NA, Not Applicable.

284

285 **Figure 1.** Patient-specific computer simulation workflow. a) Aortic root anatomical structures  
286 including native calcified leaflets segmented from preoperative CT images in Mimics (Materialize,  
287 Leuven); b,c) Aortic root anatomical structures reconstructed with FEops HEARTguide from  
288 frontal and top view respectively; d) segmentation of the VenusA valve based on postoperative CT  
289 images in Mimics; e) simulation of the VenusA implantation using FEops HEARTguide; f)  
290 evaluation of the interaction between the simulated Venus-A valve and the AML reconstructed  
291 with FEops HEARTguide.

292

293 **Figure 2.** Definition of mitral-aortic annulus distance (blue line) and mitral-aortic annulus angle.  
294 Shown is a reference plane through the center of the mitral annulus with normal vector aligned  
295 with the postero-medial and antero-lateral trigones, and the best fitting normal vectors of the  
296 mitral annulus and aortic annulus.

297

298 **Figure 3.** Representative cases of PAI and non-PAI. a) Case with no intersection between the  
299 simulated Venus-A valve and the reconstructed AML resulting in no morphological interference; b)  
300 case with limited intersection between the simulated Venus-A valve and the reconstructed AML  
301 (intersection < half cell) resulting in no morphological interference; c) case with large intersection  
302 between the simulated Venus-A valve and the reconstructed AML (intersection > half cell)  
303 resulting in morphological interference.

304

305 **Supplementary Figure 1.** Description of half one cell. a) Red arrow indicates one cell,  
306 yellow arrow indicates half cell. b) Interference less than half cell.

307



## 308 **8 Author contribution statement**

309 YW and TL contributed equally to study design, data acquisition, statistical analysis, and  
310 drafted the manuscript. JJ approved the submission of the final version. YZ, PL, DQ and SY  
311 contributed greatly to data collection and the revision of the manuscript. ND, GR and SC  
312 contributed greatly to computer simulation. All authors contributed to the article and approved the  
313 submitted version.

## 314 **9 COMPETING INTEREST**

315 Nic Debusschere and Giorgia Rocatello are employees of Feops NV. Sihang Cheng is an  
316 employee of Venus Medtech. The other authors report no disclosures of competing interest.

## 317 **10 FUNDING**

318 This work was funded by the Chongqing Talents Project (Jin Jun) and Young Doctor  
319 Incubation Program of Xinqiao Hospital (2022YQB094).

## 320 **11 Acknowledgments**

321 We would like to thank Editage ([www.editage.cn](http://www.editage.cn)) for English language editing.






## 322 **12 REFERENCES**


- 323 [1] Kalogeropoulos, A. S., Redwood, S. R., Allen, C. J., Hurrell, H., Chehab, O., Rajani, R., et al.  
324 (2022). A 20-year journey in transcatheter aortic valve implantation: Evolution to current  
325 eminence. *Frontiers in cardiovascular medicine*, 9, 971762.
- 326 [2] Tsang, W., Meineri, M., Hahn, R. T., Veronesi, F., Shah, A. P., Osten, M., et al. (2013). A  
327 three-dimensional echocardiographic study on aortic-mitral coupling in transcatheter aortic valve  
328 replacement. *European heart journal. Cardiovascular Imaging*, 14(10), 950-956.  
329 doi:10.1093/ehjci/jet058
- 330 [3] Franco, E., de Agustín, J. A., Hernandez-Antolin, R., Garcia, E., Silva, J., Maroto, L., et al.  
331 (2012). Acute mitral stenosis after transcatheter aortic valve implantation. *Journal of the*  
332 *American College of Cardiology*, 60(20), e35. doi:10.1016/j.jacc.2012.05.061
- 333 [4] Cannata, F., Regazzoli, D., Barberis, G., Chiarito, M., Leone, P. P., Lavanco, V., et al. (2019).  
334 Mitral Valve Stenosis after Transcatheter Aortic Valve Replacement: Case Report and Review of  
335 the Literature. *Cardiovascular revascularization medicine : including molecular interventions*,  
336 20(12), 1196-1202. doi:10.1016/j.carrev.2019.02.023
- 337 [5] Fotbolcu, H., & Özdemir, R. (2022). Multiple Anterior Mitral Valve Perforation After Deep  
338 Transfemoral Aortic Valve Implantation. *Brazilian journal of cardiovascular surgery*, 37(4),  
339 602-604. doi:10.21470/1678-9741-2020-0566
- 340 [6] Amat-Santos, I. J., Cortés, C., & Varela-Falcón, L. H. (2017). Delayed left anterior mitral  
341 leaflet perforation and infective endocarditis after transapical aortic valve implantation-Case  
342 report and systematic review. *Catheterization and cardiovascular interventions : official journal of*




- 343 the Society for Cardiac Angiography & Interventions, 89(5), 951-954. doi:10.1002/ccd.26410
- 344 [7] Miura, M., Isotani, A., Murata, K., Kawaguchi, T., Hayashi, M., Arai, Y., et al. (2016).  
345 Perforation of Anterior Mitral Leaflet Due to Mechanical Stimulation Late After Transcatheter  
346 Aortic Valve Replacement. *JACC. Cardiovascular interventions*, 9(24), e233-e234.  
347 doi:10.1016/j.jcin.2016.10.009
- 348 [8] Li, J., Sun, Y., Zheng, S., Li, G., Dong, H., Fu, M., et al. (2021). Anatomical Predictors of  
349 Valve Malposition During Self-Expandable Transcatheter Aortic Valve Replacement. *Frontiers in*  
350 *cardiovascular medicine*, 8, 600356. doi:10.3389/fcvm.2021.600356
- 351 [9] Schultz, C., Rodriguez-Olivares, R., Bosmans, J., Lefèvre, T., De Santis, G., Bruining, N., et  
352 al. (2016). Patient-specific image-based computer simulation for the prediction of valve  
353 morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards  
354 SAPIEN valve. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group*  
355 *on Interventional Cardiology of the European Society of Cardiology*, 11(9), 1044-1052.  
356 doi:10.4244/EIJV11I9A212
- 357 [10] Rocatello, G., El Faquir, N., De Santis, G., Iannaccone, F., Bosmans, J., De Backer, O., et al.  
358 (2018). Patient-Specific Computer Simulation to Elucidate the Role of Contact Pressure in the  
359 Development of New Conduction Abnormalities After Catheter-Based Implantation of a  
360 Self-Expanding Aortic Valve. *Circulation. Cardiovascular interventions*, 11(2), e005344.  
361 doi:10.1161/CIRCINTERVENTIONS.117.005344
- 362 [11] Liu, X., Fan, J., Mortier, P., He, Y., Zhu, Q., Guo, Y., et al. (2021). Sealing Behavior in  
363 Transcatheter Bicuspid and Tricuspid Aortic Valves Replacement Through Patient-Specific  
364 Computational Modeling. *Frontiers in cardiovascular medicine*, 8, 732784.  
365 doi:10.3389/fcvm.2021.732784
- 366 [12] Dowling, C., Bavo, A. M., El Faquir, N., Mortier, P., de Jaegere, P., De Backer, O., et al.  
367 (2019). Patient-Specific Computer Simulation of Transcatheter Aortic Valve Replacement in  
368 Bicuspid Aortic Valve Morphology. *Circulation. Cardiovascular imaging*, 12(10), e009178.  
369 doi:10.1161/CIRCIMAGING.119.009178
- 370 [13] Dowling, C., Firoozi, S., & Brecker, S. J. (2020). First-in-Human Experience With  
371 Patient-Specific Computer Simulation of TAVR in Bicuspid Aortic Valve Morphology. *JACC.*  
372 *Cardiovascular interventions*, 13(2), 184-192. doi:10.1016/j.jcin.2019.07.032
- 373 [14] Dowling, C., Gooley, R., McCormick, L., Firoozi, S., & Brecker, S. J. (2021).  
374 Patient-specific Computer Simulation: An Emerging Technology for Guiding the Transcatheter  
375 Treatment of Patients with Bicuspid Aortic Valve. *Interventional cardiology (London, England)*,  
376 16, e26. doi:10.15420/icr.2021.09
- 377 [15] Sievers, H. H., & Schmidtke, C. (2007). A classification system for the bicuspid aortic valve  
378 from 304 surgical specimens. *The Journal of thoracic and cardiovascular surgery*, 133(5),  
379 1226-1233. doi:10.1016/j.jtcvs.2007.01.039
- 380 [16] VARC-3 WRITING COMMITTEE, Généreux, P., Piazza, N., Alu, M. C., Nazif, T., Hahn, R.  
381 T., Pibarot, P., et al. (2021). Valve Academic Research Consortium 3: updated endpoint definitions

- 382 for aortic valve clinical research. *European heart journal*, 42(19), 1825-1857. doi:  
383 10.1093/eurheartj/ehaa799
- 384 [17] Nappi, F., Nenna, A., Timofeeva, I., Mihos, C., Gentile, F., & Chello, M. (2020). Mitral  
385 regurgitation after transcatheter aortic valve replacement. *Journal of thoracic disease*, 12(5),  
386 2926-2935. doi:10.21037/jtd.2020.01.69
- 387 [18] Wang, Y., Yu, S., Qian, D., Li, J., Fang, Z., Cheng, W., et al. (2022) Anatomic predictor of  
388 severe prosthesis malposition following transcatheter aortic valve replacement with  
389 self-expandable Venus-A Valve among pure aortic regurgitation: A multicenter retrospective study.  
390 *Frontiers in cardiovascular medicine*, 9:1002071. doi: 10.3389/fcvm.2022.1002071
- 391 [19] Raschpichler, M., Seeburger, J., Strasser, R. H., & Misfeld, M. (2014). Corevalve prosthesis  
392 causes anterior mitral leaflet perforation resulting in severe mitral regurgitation and subsequent  
393 endocarditis. *European heart journal*, 35(24), 1587. doi:10.1093/eurheartj/ehf503
- 394 [20] Sanna, G. D., Moccia, E., Pepi, M., & Parodi, G. (2020). Anterior Mitral Leaflet Perforation  
395 and Infective Endocarditis Following Transcatheter Aortic Valve Replacement in a Patient  
396 Presenting with Heart Failure. *Journal of cardiovascular echography*, 30(1), 44–46.  
397 doi:10.4103/jcecho.jcecho\_52\_19
- 398 [21] Xiong, T. Y., Stoppani, E., De Beule, M., Chen, F., Li, Y. J., Liao, Y. B., Feng, Y., de Jaegere,  
399 P., & Chen, M. (2021). Force distribution within the frame of self-expanding transcatheter aortic  
400 valve: Insights from in-vivo finite element analysis. *Journal of biomechanics*, 128, 110804.  
401 doi:10.1016/j.jbiomech.2021.110804
- 402 [22] Han, Y., Ribeiro, J. M., de Jaegere, P. P. T., & Zhang, G. (2021). TAVR in a Patient With  
403 Quadricuspid Aortic Stenosis: The Role of Patient-Specific Computer Simulation in Treatment  
404 Planning and Outcome Prediction. *JACC. Cardiovascular interventions*, 14(9), e93-e95.  
405 doi:10.1016/j.jcin.2021.01.014
- 406 [23] Moldovan, H., Popescu, B. Ş., Nechifor, E., Badea, A., Ciomaga, I., Nica, C., Zaharia, O.,  
407 Gheorghişă, D., Broască, M., Diaconu, C., Parasca, C., Chioncel, O., & Iliescu, V. A. (2022). Rare  
408 Cause of Severe Mitral Regurgitation after TAVI: Case Report and Literature Review. *Medicina*  
409 (Kaunas, Lithuania), 58(4), 464. doi:10.3390/medicina58040464
- 410 [24] Amat-Santos, I. J., Cortés, C., Nombela Franco, L., Muñoz-García, A. J., Suárez De Lezo, J.,  
411 Gutiérrez-Ibañes, E., et al. (2017). Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve  
412 Replacement Recipients: A Multicenter Analysis. *JACC. Cardiovascular interventions*, 10(19),  
413 1973-1981. doi:10.1016/j.jcin.2017.07.045
- 414 [25] Li, L., Liu, Y., Jin, P., Tang, J., Lu, L., et al. (2021). Effect of Eccentric Calcification of an  
415 Aortic Valve on the Implant Depth of a Venus-A Prosthesis During Transcatheter Aortic Valve  
416 Replacement: A Retrospective Study. *Frontiers in physiology*, 12, 718065.  
417 doi:10.3389/fphys.2021.718065

418







**Table 1 Baseline characteristics of PAI group and Non-PAI group**

	PAI group (n=9)	Non-PAI group (n=11)	P value
<b>Clinical data</b>			
Male gender	3/9	5/11	0.670
Age (yrs)	69.1±6.2	72.3±7.1	0.302
Body mass index (Kg/m <sup>2</sup> )	24.5±4.8	25.4±4.3	0.645
Coronary heart disease	2/9	2/11	1.000
Atrial fibrillation	5/9	1/11	0.050*
Hypertension	4/9	5/11	1.000
Diabetes	0/9	2/11	0.479
NYHA class III/IV	7/9	5/11	0.197
STS score (%)	4.5±1.6	4.2±1.8	0.726
<b>Ultrasound data</b>			
Left atrium anteroposterior diameter (mm)	41.4±6.9	37.1±4.9	0.115
Left ventricle anteroposterior diameter (mm)	52.0±6.0	45.8±4.2	0.015*
Interventricular septum thickness (mm)	12.8±1.4	13.7±2.2	0.283
Ejection fraction (%)	59.9±6.0	64.8±3.5	0.039*
Fraction shortening (%)	31.9±4.0	35.4±2.6	0.036*
Peak aortic flow velocity (cm/s)	466.9±58.1	507.6±70.5	0.182
Mean aortic valve pressure gradient (mmHg)	49.0±12.9	57.6±16.0	0.207
≥Mild mitral regurgitation	8/9	4/11	0.028*
≥Moderate mitral regurgitation	3/9	0/11	0.074
≥Moderate aortic regurgitation	4/9	2/11	0.336
<b>Feops data</b>			
Distance between aortic / mitral planes (mm)	2.7±1.7	5.0±2.2	0.019*
Angle between aortic / mitral planes (degree)	131.4±11.6	126.2±11.5	0.333
<b>CT data</b>			
Bicuspid	5/9	7/11	1.000
Type 0	4/5	3/7	
Type 1	1/5	4/7	
Aortic annulus			
Mean diameter (mm)	24.2±1.6	22.2±1.6	0.016*
Perimeter (mm)	76.5±5.6	69.5±5.4	0.011*
Area (mm <sup>2</sup> )	451.6±57.5	382.3±54.0	0.013*
Left ventricular outflow tract perimeter (mm)	83.9±7.5	64.8±15.4	0.003*
Sinotubular Junction mean diameter (mm)	31.8±4.6	29.0±3.3	0.144
Aortic angulation (degree)	49.7± 8.7	50.5±15.8	0.895
NCC calcification score (mm <sup>3</sup> )	52.2 (22.9,79.1)	156.0 (3.1, 246.2)	0.046*
RCC calcification score (mm <sup>3</sup> )	129.6 (51.7, 254.6)	167.5 (85.6, 268.3)	0.412
LCC calcification score (mm <sup>3</sup> )	115.7 (37.2, 290.5)	43.5 (4.9, 146.3)	0.295
Total leaflet calcification score (mm <sup>3</sup> )	243.6 (127.3, 589.1)	397.3 (144.0, 588.6)	0.656

Data are presented as mean ± standard deviation or median (lower quartile, upper quartile).PAI, Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons. NCC, Non coronary cusp; RCC, Right coronary cusp; LCC, Left coronary cusp.

**Table 2 Intra-Procedural data and in-hospital outcomes of the two groups.**

	PAI group (n=9)	Non-PAI group (n=11)	P value
<i>Prosthesis size</i>			<b>0.013*</b>
L23	2/9	9/11	
L26	4/9	2/11	
L29	3/9	0/11	
Implantation depth at NCC (mm)	12.2±3.3	6.2±2.9	<b>&lt;0.001*</b>
Implantation depth at LCC (mm)	14.3±4.7	7.7±3.1	<b>0.002*</b>
Pre dilatation	9/9	11/11	NA
Post dilatation	1/9	6/11	0.070
Coronary obstruction	0/9	1/11	1.000
New onset atrial fibrillation	0/9	1/11	1.000
New onset LBBB	7/9	3/11	0.070
Need of permanent pacemaker	1/9	2/11	1.000
Major bleeding	0/9	1/11	1.000
≥Moderate perivalvular leakage	5/9	0/11	<b>0.008*</b>
Peak aortic flow velocity (cm/s)	271.7±33.2	273.5±50.5	0.928
Mean aortic valve pressure gradient (mmHg)	15.0±3.8	16.9±7.5	0.497
≥Mild mitral regurgitation	7/9	3/11	0.070
≥Moderate mitral regurgitation	2/9	1/11	0.566

Data are presented as mean ± standard deviation.

PAI, Prosthesis-anterior mitral leaflet interference; NCC, Non coronary cusp; LCC, Left coronary cusp. LBBB, left bundle branch block. NA, Not Applicable.



**Table 3 The 30-day and 12-month clinical outcomes of the two groups**

	PAI group (n=9)	Non-PAI group (n=11)	P value
<b>30-day outcome</b>			
Peak aortic flow velocity (cm/s)	256.5±42.3	281.7±60.1	0.483
Mean aortic valve pressure gradient (mmHg)	13.6±4.5	17.5±7.6	0.312
Mean mitral valve pressure gradient (mmHg)	1.6±0.6	1.5 (1.0, 2.1)	0.945
≥Mild mitral stenosis	0/9	0/11	NA
≥Moderate mitral regurgitation	2/9	2/11	0.625
≥Moderate perivalvular leakage	4/9	1/11	0.127
NYHA class III/IV	4/9	1/11	0.127
Stroke	0/9	0/11	NA
All-cause mortality	0/9	0/11	NA
Infective endocarditis	0/9	0/11	NA
Mitral valve perforation	0/9	0/11	NA
<b>12-month outcome</b>			
Peak aortic flow velocity (cm/s)	279.7±22.6	292.6±64.1	0.681
Mean aortic valve pressure gradient (mmHg)	15.0±2.9	19.4±8.2	0.191
Mean mitral valve pressure gradient (mmHg)	1.9±1.4	1.5 (1.0, 2.0)	0.964
≥Mild mitral stenosis	0/9	0/11	NA
≥Moderate mitral regurgitation	3/9	1/11	0.217
≥Moderate perivalvular leakage	4/9	1/11	0.127
NYHA class III/IV	1/9	0/11	0.450
Stroke	0/9	0/11	NA
All-cause mortality	0/9	0/11	NA
Infective endocarditis	0/9	0/11	NA
Mitral valve perforation	0/9	0/11	NA

Data are presented as mean ± standard deviation or median (lower quartile, upper quartile).

PAI, Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; NA, Not Applicable.